We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Cyprotex | LSE:CRX | London | Ordinary Share | GB00BP25RZ14 | ORD £0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 160.50 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
10/9/2016 23:09 | Register to get INVESTEGATE.CO.UK alerts and you will receive automatically. The £ is no doubt helping too. Hard to forecast revenue when so many growth drivers come together at once. | p1nkfish | |
09/9/2016 11:32 | Thanks again - life is indeed a continuous learning curve. Still seems odd that they chose to use this method of dissemination given that many other similar announcements have been made through the standard form of RNS. | husbod | |
09/9/2016 11:23 | They don't normally show in the news section on the advfn monitor screen but do appear in the news section on the individual company b/board. | battlebus2 | |
09/9/2016 11:21 | Thanks battlebus - not knowingly seen it before. Your post 72 suggests that this type of announcement would not be a widely seen as the normal RNS - why, might I ask, is that? | husbod | |
09/9/2016 11:00 | It's usually used for non price sensitive information...... | battlebus2 | |
09/9/2016 10:54 | What's an RNSNON and why would they release this news in this way when everything else has been by way of standard RNS? Is it cheaper or something? Anyway it's unalloyed good news and just more evidence of our company's development. Just need to know the outcome of the reorganisation process although the old saying "if it aint broke don't fix it" comes to mind. Saltaire - whatever the form of announcement it was that that triggered the share price rise - I would suggest that if anyone "was sniffing around" the uplift would have been far higher. | husbod | |
08/9/2016 22:28 | It was an RNSNON not an RNS so most wouldn't have seen it. | battlebus2 | |
08/9/2016 22:24 | There was news this morning. | this_is_me | |
08/9/2016 21:18 | Why the big move today on no news? Someone sniffing around? Salty | saltaire111 | |
08/9/2016 11:21 | Revenue is up 25% in a year so word must be spreading. | this_is_me | |
08/9/2016 08:25 | This really is the premier ADMEtox assay Co. About time people woke up to that fact. | bahiflyer | |
08/9/2016 08:21 | New highs this morning on the back of the rnsnon.... | battlebus2 | |
01/9/2016 17:40 | SBS taken private at about £60M, could happen to CRX as part of same vehicle, Sherwood. The review of strategy will be very interesting. SBS, CRX could have made a combo. Harwood, Trident etc related. | p1nkfish | |
31/8/2016 10:32 | Two nice bits of kit they've had installed to help keep ahead of the competition and take them into new markets. Dr Anthony Baxter, Cyprotex's Chief Executive Officer, comments: "As we expand into new markets, our analytical capabilities need to diversify to meet the requirements for different types of molecules. Cyprotex now have an impressive range of analytical separation and detection capabilities enabling us to tackle more challenging molecules with the greatest chance of success." | bahiflyer | |
16/8/2016 15:49 | Me too. However, I sold 10k shares this morning (a very small bit of top slicing) and the share price didn't change at all. It looks to me as if they want shares but given the spread don't want to sell any. Now why would that be? | husbod | |
16/8/2016 11:48 | Why convert when they offer 5% and 60p conversion price at end? I'm holding mine tightly. | p1nkfish | |
16/8/2016 11:47 | We should see the float increase in that case? | p1nkfish | |
16/8/2016 11:38 | P1inkfish - I think those odd buys at the bid price might in fact be Convertible Loan Note holders converting all or part of their holdings into shares - it's that time of year. It would be interesting to know in October what the nominal value of the outstanding Convertible Loan Notes actually is. I don't suppose that there will have been a material reduction though. | husbod | |
15/8/2016 11:26 | And Mr Ingram bought another 25k on 12/8 I wonder if that's him buying that 25k today. Something going on cos the share price doesn't shift whatever the trades or at least it hasn't over the last few weeks. Usually of course, given how tightly the shares are held, the price moves on modest trades either way. Are Mr Ingram and the mysterious "Cyprotex plc " buyer hoovering up any shares that become available? | husbod | |
15/8/2016 10:35 | Another RNS of the same nature today where the purchase price is clearly the bid price and the sale price is clearly the offer. And the latter is of the same amount as todays actual trade so it looks as if another RNS of the same type will be issued tomorrow. Surely, p1nkfish if its an employee then his or her name should be given. And if it's part of an employee bonus scheme then it should be stated as such. All rather odd unless maybe the company is buying in shares so as to exchange them for value for loan note holders? But in that case wouldn't they have to declare this strategy or has a resolution been passed to allow a certain amount of share buy backs? Je suis confused. Or to be more accurate more than usually confused. | husbod | |
13/8/2016 10:32 | Reads that the principal trader is connected to cyprotex but can't be sure it is the company. Might be employees that need to declare relationship but at below director level so no need to notify full details to market. I will still hold anyway as I am convinced this is a gem. | p1nkfish | |
13/8/2016 10:23 | Haven't looked Husbod. Will do so but don't hold your breath for me to be able to throw much light on it. | p1nkfish |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions